These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29315431)

  • 1. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    Schrijver WAME; Suijkerbuijk KPM; van Gils CH; van der Wall E; Moelans CB; van Diest PJ
    J Natl Cancer Inst; 2018 Jun; 110(6):568-580. PubMed ID: 29315431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor conversion in distant breast cancer metastases.
    Hoefnagel LD; van de Vijver MJ; van Slooten HJ; Wesseling P; Wesseling J; Westenend PJ; Bart J; Seldenrijk CA; Nagtegaal ID; Oudejans J; van der Valk P; van der Groep P; de Vries EG; van der Wall E; van Diest PJ
    Breast Cancer Res; 2010; 12(5):R75. PubMed ID: 20863372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient.
    Hoefnagel LD; van der Groep P; van de Vijver MJ; Boers JE; Wesseling P; Wesseling J; ; van der Wall E; van Diest PJ
    Ann Oncol; 2013 Dec; 24(12):3017-23. PubMed ID: 24114857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution.
    Chen R; Qarmali M; Siegal GP; Wei S
    Mod Pathol; 2020 Dec; 33(12):2499-2506. PubMed ID: 32620918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.
    Duchnowska R; Dziadziuszko R; Trojanowski T; Mandat T; Och W; Czartoryska-Arłukowicz B; Radecka B; Olszewski W; Szubstarski F; Kozłowski W; Jarosz B; Rogowski W; Kowalczyk A; Limon J; Biernat W; Jassem J;
    Breast Cancer Res; 2012 Aug; 14(4):R119. PubMed ID: 22898337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases.
    Hoefnagel LD; Moelans CB; Meijer SL; van Slooten HJ; Wesseling P; Wesseling J; Westenend PJ; Bart J; Seldenrijk CA; Nagtegaal ID; Oudejans J; van der Valk P; van Gils CH; van der Wall E; van Diest PJ
    Cancer; 2012 Oct; 118(20):4929-35. PubMed ID: 22415862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Kaidar-Person O; Meattini I; Jain P; Bult P; Simone N; Kindts I; Steffens R; Weltens C; Navarria P; Belkacemi Y; Lopez-Guerra J; Livi L; Baumert BG; Vieites B; Limon D; Kurman N; Ko K; Yu JB; Chiang V; Poortmans P; Zagar T
    Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
    Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
    Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients.
    Nguyen TH; Nguyen VH; Nguyen TL; Qiuyin C; Phung TH
    Biomed Res Int; 2019; 2019():7391237. PubMed ID: 31583246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.
    Berghuis AMS; van Deurzen CHM; Koffijberg H; Terstappen LWMM; Sleijfer S; IJzerman MJ
    Breast Cancer Res Treat; 2019 Jun; 175(2):451-458. PubMed ID: 30756285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
    Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERα-36 regulates progesterone receptor activity in breast cancer.
    Konan HP; Kassem L; Omarjee S; Surmieliova-Garnès A; Jacquemetton J; Cascales E; Rezza A; Trédan O; Treilleux I; Poulard C; Le Romancer M
    Breast Cancer Res; 2020 May; 22(1):50. PubMed ID: 32429997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer.
    Vogel C; Malter W; Morgenstern B; Ludwig S; Vehreschild JJ; Hamacher S; Mallmann P; Kirn V; Thangarajah F
    Anticancer Res; 2019 May; 39(5):2647-2659. PubMed ID: 31092464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study.
    Yi ZB; Yu P; Zhang S; Wang WN; Han YQ; Ouyang QC; Yan M; Wang XJ; Hu XC; Jiang ZF; Huang T; Tong ZS; Wang SS; Yin YM; Li H; Yang RX; Yang HW; Teng YE; Sun T; Cai L; Li HY; Chen X; He JJ; Liu XL; Yang SE; Wang JY; Fan JH; Qiao YL; Xu BH
    Int J Cancer; 2021 Feb; 148(3):692-701. PubMed ID: 32700765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.
    Dodson A; Parry S; Ibrahim M; Bartlett JM; Pinder S; Dowsett M; Miller K
    J Pathol Clin Res; 2018 Oct; 4(4):262-273. PubMed ID: 30066480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study.
    de Dueñas EM; Hernández AL; Zotano AG; Carrión RM; López-Muñiz JI; Novoa SA; Rodríguez AL; Fidalgo JA; Lozano JF; Gasión OB; Carrascal EC; Capilla AH; López-Barajas IB; Mateu MM; de Ceballos Reyna MH; Ferrando AO; Jañez NM; Ballerini VC; Torres AA; Catalán G; Sáenz JA; Menjón S; González-Angulo AM
    Breast Cancer Res Treat; 2014 Feb; 143(3):507-15. PubMed ID: 24414130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 Receptor Conversion Is a strong Survival Predictor in Patients with Breast Cancer Brain Metastases.
    Michel A; Oppong MD; Rauschenbach L; Pierscianek D; Dinger TF; Schmidt T; Hense J; Pöttgen C; Kimmig R; Ahmadipour Y; Özkan N; Müller O; Junker A; Sure U; Jabbarli R; El Hindy N
    World Neurosurg; 2021 Aug; 152():e332-e343. PubMed ID: 34062302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).
    Thompson AM; Jordan LB; Quinlan P; Anderson E; Skene A; Dewar JA; Purdie CA;
    Breast Cancer Res; 2010; 12(6):R92. PubMed ID: 21059212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.